Abstract: Memory devices and methods of operating memory devices in which refresh management operations can be scheduled on an as-needed basis for those memory portions where activity (e.g., activations in excess of a predetermined threshold) warrants a refresh management operation are disclosed. In one embodiment, an apparatus comprises a memory including a memory location, and circuitry configured to determine a count corresponding to a number of activations at the memory location, to schedule a refresh management operation for the memory location in response to the count exceeding a first predetermined threshold, and to decrease the count by an amount corresponding to the first predetermined threshold in response to executing the scheduled refresh management operation. The circuitry may be further configured to disallow, in response to determining that the count has reached a maximum permitted value, further activations at the memory location until after the count has been decreased.

Abstract: A system may include a memory and a processor in communication with the memory. The processor may be configured to perform operations. The operations may include registering a custom resource definition for a tenant with a host and scaling a controller for the customer resource definition. The operations may include generating a replication using the customer resource definition, injecting information into the replication, and syncing a status of the custom resource definition between the host and the tenant.

Abstract: A computer-implemented method, an apparatus, and a computer program product for edge node autonomy. For a first edge node of a plurality of edge nodes in a federation in a distributed computing framework, one or more processors receive a request to be sent to a central node in the distributed computing framework. The one or more processors determine whether the federation is connected to the central node. In response to determining that the federation is not connected to the central node, the one or more processors determine whether a controller capable of processing the request is available in the federation. In response to determining that the controller capable of processing the request is available in the federation, the one or more processors notify the controller to process the request.

Abstract: A cationic hyaluronic acid coated spanlastic, comprising a drug-loaded vesicle. The surface of the drug-loaded vesicle is modified by cationic hyaluronic acid, the drug-loaded vesicle comprises a vesicle membrane and a hydrophobic drug wrapped by the vesicle membrane, and the vesicle membrane comprises a nonionic surfactant and an edge activator.

Abstract: A method of determining an analyte concentration in a sample by a sensor is disclosed. The method includes analyzing a sample signal generated by the sensor for an analyte being measured. If the sample signal is normal, the method includes comparing the sample signal with a first reference signal of a reference solution measured prior to measuring the sample in order to determine the analyte concentration. If the sample signal is abnormal, the method includes comparing the sample signal with a calculated reference signal point obtained by interpolation between the first reference signal and a second reference signal of the same reference solution measured after measuring the sample. Various methods of determining and handling errors based on signal patterns are also disclosed.

Abstract: A method of determining an analyte concentration in a sample by a sensor is disclosed. The method includes analyzing a sample signal generated by the sensor for an analyte being measured. If the sample signal is normal, the method includes comparing the sample signal with a first reference signal of a reference solution measured prior to measuring the sample in order to determine the analyte concentration. If the sample signal is abnormal, the method includes comparing the sample signal with a calculated reference signal point obtained by interpolation between the first reference signal and a second reference signal of the same reference solution measured after measuring the sample. Various methods of determining and handling errors based on signal patterns are also disclosed.

Abstract: A method of determining an analyte concentration in a sample by a sensor is disclosed. The method comprises analyzing a sample signal generated by the sensor for an analyte being measured. If the sample signal is normal, the method comprises comparing the sample signal with a first reference signal of a reference solution measured prior to measuring the sample in order to determine the analyte concentration. If the sample signal is abnormal, the method comprises comparing the sample signal with a calculated reference signal point obtained by interpolation between the first reference signal and a second reference signal of the same reference solution measured after measuring the sample. Various methods of determining and handling errors based on signal patterns are also disclosed.

Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.

Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.

Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.

Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.

Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.

Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.

Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Abstract: The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-? (A?) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.

Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.

Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.